Key Insights on Legend Biotech – A Stock Overview

Shares of Legend Biotech have moved -2.1% today, and are now trading at a price of $45.57. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 965,307 compared to the stock's average volume of 1,212,834.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Based in Somerset, United States the company has 2,000 full time employees and a market cap of $8,306,636,800.

The company is now trading -45.08% away from its average analyst target price of $82.98 per share. The 19 analysts following the stock have set target prices ranging from $60.0 to $95.0, and on average give Legend Biotech a rating of buy.

Over the last 12 months LEGN shares have declined by -33.3%, which represents a difference of -56.5% when compared to the S&P 500. The stock's 52 week high is $77.32 per share and its 52 week low is $38.6. Based on Legend Biotech's average net margin growth of 15.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2024 93,991 -59,793 -64 64.84
2023 285,143 -518,254 -182 52.23
2022 117,005 -446,349 -381 34.98
2021 68,826 -403,582 -586 -65.07
2020 75,000 -266,373 -355 -110.06
2019 59,980 -101,590 -169
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.